Form 4: Avidity Director Disposes Shares, Options in Novartis Merger

Avidity Biosciences director Tamar Thompson disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger agreement with Novartis AG.

Summary

• Tamar Thompson, a Director of Avidity Biosciences, Inc. (RNAM), reported the disposition of securities.
• The transactions occurred on February 27, 2026, pursuant to an Agreement and Plan of Merger dated October 25, 2025.
• Novartis AG and its indirect wholly owned subsidiary, Ajax Acquisition Sub, Inc., are the acquiring entities.
• Thompson disposed of 6,692 shares of Common Stock, including shares issuable upon settlement of previously reported restricted stock units.
• Multiple tranches of stock options were also disposed of, totaling 67,523 options.
• The disposed stock options include: 10,034 options with an exercise price of $33.62, 13,489 options at $39.96, 22,000 options at $12.48, and 22,000 options at $12.03.
• Stock options were exchanged for a cash payment equal to the excess of the merger consideration of $72.00 over their respective exercise prices.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development for shareholders, as the merger consideration of $72.00 per share represents a significant premium, leading to the disposition of shares and options in a value-accretive transaction.

Positives

• The merger consideration of $72.00 per share represents a significant value for Avidity Biosciences shareholders.
• Option holders received a cash payment for the in-the-money value of their options, reflecting a positive outcome from the merger.

Future Outlook

The filing indicates the anticipated completion of the merger with Novartis AG by February 27, 2026, leading to the disposition of Avidity Biosciences securities as per the merger agreement terms.

Industry Context

StockSavvy.ai notes this transaction reflects the ongoing consolidation trend in the biotechnology sector, where larger pharmaceutical companies like Novartis acquire innovative smaller firms such as Avidity Biosciences for their pipeline and technology, often at a significant premium.

Comparison to Industry Standards

• The merger consideration of $72.00 per share represents a substantial premium over Avidity Biosciences' pre-announcement trading price, which is typical for strategic acquisitions in the biotech sector aiming to secure promising assets.
• Similar acquisitions in the biotech space, such as Gilead Sciences' acquisition of Immunomedics for $21 billion (approximately $88 per share) or Bristol Myers Squibb's acquisition of Celgene for $74 billion, often involve significant premiums to gain access to novel drug platforms and pipelines.

Stakeholder Impact

• Shareholders of Avidity Biosciences will receive $72.00 per share in cash upon the completion of the merger.
• Holders of in-the-money stock options will receive cash payments for the intrinsic value of their options.

Next Steps

• Completion of the merger with Novartis AG, as indicated by the future transaction date.

Key Dates

Recommendation

The filing details the disposition of shares and options by a director in anticipation of the merger with Novartis AG, indicating the transaction is proceeding as planned. For existing shareholders, holding until the merger's completion to receive the $72.00 per share consideration is the logical action.

Keywords

Avidity Biosciences, RNAM, Novartis, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Common Stock, Director Disposition